We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development
News

Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development

Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development
News

Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical Development"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Xceleron has announced that, following signature of a Master Services Agreement with Sanofi-Aventis Deutschland GmbH, a number of studies are underway to assess the human metabolism of novel compounds in early clinical development. This work utilises Xceleron’s ultra-sensitive Accelerator Mass Spectrometry (AMS) technology platform.

This latest deal adds to Xceleron’s growing client list of major organisations – including 15 of the world’s top 20 pharma companies.

Xceleron’s foundation in 1997 was supported by GSK, Novartis, Pfizer and Janssen (now Johnson & Johnson). Notably after many years of working with Xceleron to explore the potential of AMS, GSK now have 2 AMS machines of their own - focused specifically on similar kinds of metabolite profiling studies to those now being undertaken by Sanofi-Aventis.

Advertisement